Last updated on April 18, 2014 at 21:21 EDT

Elsevier and Russian Foundation of Basic Research Sign SciVerse ScienceDirect Access Agreement

February 1, 2012

AMSTERDAM, February 1, 2012 /PRNewswire/ –

150 Russian research institutes involved in long-term collaboration

Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, today announced it has reached an agreement
with the Russian Foundation of Basic Research (RFBR) to provide 150 Russian research
institutes with access to SciVerse ScienceDirect
[http://www.info.sciverse.com/sciencedirect ] as well as trial access to SciVerse Scopus.
This one-year license agreement is part of a formal collaboration program between Elsevier
and RFBR until 2014.

Academician Prof. Vladislav Panchenko, Chairman of the RFBR Board, said of the
agreement, “Access to up-to-date scientific information is a necessary element for
researchers in their workflow. That is why we are glad to see us collaborate so closely
with Elsevier, providing our scientists with access to a quarter of the world’s scientific
research. We are happy for this continuous and mutually beneficial cooperation. We hope
that together we will drive Russian science to the top of global scientific scene.”

Igor Osipov, PhD, Elsevier Regional Director for Russia and Belarus added, “RFBR and
its leadership has become a true partner to us – we organize joint events, run training
programs across the country and strive to support and reward Russian researchers with the
best available content and solutions. With this new agreement, our joint work in bringing
best Russian science to the international arena and supporting Russian government efforts
in building better and efficient research shall be continued in the years to come.”

About the Russian Foundation for Basic Research

The Russian Foundation for Basic Research [http://www.rfbr.ru/rffi/eng/about/n_601 ]
is a self-governing foundation existing in the form of a federal institution run under the
jurisdiction of the government of the Russian Federation. Its main goal is to provide
support and assistance to research work in all areas of fundamental science on a
competitive basis and which is called upon to build new relationships between scientists
and the state. The foundation distributes federal funding to the most advanced research
projects originating both from Russian universities as well as from institutions of the
Russian Academy of Sciences. The RFBR is part of G8 scientific foundations family and
enjoys close cooperation ties with all key funding bodies across the globe: from North
America to EU, China and Japan. Financing refereed projects across disciplines, key
attention is given to physics, technology and nano-technology, medicine, various
interdisciplinary studies, which Russian government identified as priority in R&D
development until 2020.

About the Elsevier SciVerse Suite

The SciVerse(R) [http://www.hub.sciverse.com/action/home ] suite of search and
discovery offerings provides the global research community access to a constantly
expanding universe of content and solutions which can now be accessed in one platform. The
suite currently includes SciVerse ScienceDirect(R) [http://www.sciencedirect.com ], the
world’s largest source of peer-reviewed content containing more than 10 million articles,
and SciVerse Scopus(R) [http://www.scopus.com/home.url ], an abstract and citation
database containing 41 million records, 70% with abstracts and nearly 19,500 titles from
5,000 publishers worldwide. The platform also includes SciVerse Hub
[http://www.hub.sciverse.com/action/home ] which enables researchers to perform a single
search across all of the SciVerse content as well as targeted web content with results
ranked by relevancy and without duplication. Applications
[http://www.applications.sciverse.com/action/userhome ] and Developer Network
[http://www.developers.sciverse.com ] allow the scientific community to build, find and
use applications that enhance the SciVerse research experience.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include SciVerse(R) ScienceDirect(R) [http://www.sciencedirect.com ],
SciVerse(R) Scopus(R) [http://www.scopus.com/home.url ], Reaxys(R) [https://www.reaxys.com
], MD Consult [http://www.mdconsult.com ] and Nursing Consult
[http://www.nursingconsult.com ], which enhance the productivity of science and health
professionals, and the SciVal(R) suite [http://www.scival.com ] and MEDai’s Pinpoint
Review [http://www.medai.com ], which help research and health care institutions deliver
better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading publisher and information provider, which
is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN
(Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

        Media contact
        Galina Yakshonak
        Elsevier, Russia

SOURCE Elsevier

Source: PR Newswire